Pancreatic Cancer Research

ResearcherKansai Medical UniversityNo recent work listed

Taketo Yamaguchi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5068601802. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
79
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 5 papers · 2018: none · 2019: 2 papers · 2020: none · 2021: 1 paper

Papers 16

  1. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  2. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  3. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Last author DOI 10.1038/s41598-019-52486-x↗
  4. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. Last author DOI 10.1007/s00280-017-3350-5↗
  5. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gem… Co-author DOI 10.1007/s00280-017-3351-4↗
  6. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  7. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2016.436↗
  8. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  9. A case of needle tract seeding after EUS-guided FNA in pancreatic cancer, detected by serial positron emission tomography/CT. First author DOI 10.1016/j.gie.2016.01.060↗
  10. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.12.362↗
  11. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2323-6↗
  12. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Last author DOI 10.1007/s00280-013-2368-6↗
  13. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  14. Usefulness of brush cytology combined with pancreatic juice cytology in the diagnosis of pancreatic cancer: significance of pancreatic juice cytology after bru… Co-author DOI 10.1097/mpa.0b013e31825d60fc↗
  15. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. First author DOI 10.1007/s00280-010-1311-3↗
  16. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. First author DOI 10.1016/j.ijrobp.2010.01.027↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junji Furuse · 8 shared papers, 2013–2021 · strength 0.44
  2. Tatsuya Ioka · 7 shared papers, 2013–2021 · strength 0.40
  3. Kentaro Sudo · 7 shared papers, 2011–2019 · strength 0.40
  4. Takuji Okusaka · 7 shared papers, 2013–2021 · strength 0.39
  5. Hiroshi Ishii · 4 shared papers, 2016–2021 · strength 0.29
  6. Emiri Kita · 3 shared papers, 2016–2019 · strength 0.28
  7. Nobumasa Mizuno · 4 shared papers, 2017–2021 · strength 0.27
  8. Masafumi Ikeda · 4 shared papers, 2013–2021 · strength 0.24
  9. Shinichi Ohkawa · 5 shared papers, 2013–2017 · strength 0.22
  10. Makoto Ueno · 3 shared papers, 2017–2021 · strength 0.22
  11. Shoji Nakamori · 3 shared papers, 2017–2021 · strength 0.21
  12. Narikazu Boku · 4 shared papers, 2013–2019 · strength 0.20
  13. Akiko Tsujimoto · 2 shared papers, 2017–2019 · strength 0.18
  14. Masao Tanaka · 4 shared papers, 2013–2017 · strength 0.18
  15. Akihiro Funakoshi · 4 shared papers, 2013–2017 · strength 0.17
  16. Shinichi Egawa · 4 shared papers, 2013–2017 · strength 0.16
  17. Hiroaki Yanagimoto · 3 shared papers, 2013–2021 · strength 0.15
  18. Hideki Ueno · 3 shared papers, 2013–2019 · strength 0.15
  19. Takashi Hatori · 3 shared papers, 2013–2017 · strength 0.13
  20. Ann‐Lii Cheng · 3 shared papers, 2013–2017 · strength 0.13
  21. Yasuo Ohashi · 3 shared papers, 2013–2017 · strength 0.13
  22. Kenji Yamao · 3 shared papers, 2013–2017 · strength 0.13
  23. Akira Fukutomi · 2 shared papers, 2013–2021 · strength 0.12
  24. Wataru Takayama · 1 shared paper, 2019 · strength 0.10
  25. Satoaki Nakamura · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.